<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01179828</url>
  </required_header>
  <id_info>
    <org_study_id>KEK 213/09</org_study_id>
    <secondary_id>grant: SPUM no. 33CM30_124117</secondary_id>
    <nct_id>NCT01179828</nct_id>
  </id_info>
  <brief_title>Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain (Predictio)</brief_title>
  <acronym>Predictio</acronym>
  <official_title>Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aalborg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drug therapy in patients with chronic low back pain is a major challenge for physicians. One&#xD;
      of the problems is the lacking knowledge in prediction of drug efficacy in a chosen patient.&#xD;
      Usually one of the classes of pain medication is given to patients with a similar clinical&#xD;
      picture, although different pain mechanisms may be responsible for this clinical picture.&#xD;
&#xD;
      Another reason for variable drug efficacy are genetic polymorphisms, this may be the reason&#xD;
      why an unique drug produces different responses (from a lacking analgesic effect up to&#xD;
      excessive effect or side-effects.&#xD;
&#xD;
      Quantitative sensory testing is a method that documents alterations in the pain perception&#xD;
      system. Linking genetic polymorphisms to quantitative sensory testing may give us a tool for&#xD;
      anticipation of drug efficacy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background&#xD;
&#xD;
      Drug therapy is an essential part of pain treatment. However, only a minor part of pain&#xD;
      patients benefits from the available treatments or is able to tolerate the drugs. One&#xD;
      important limitation of drug therapy is lack of instruments to predict their effect. Indeed,&#xD;
      in clinical practice &quot;classes&quot; of drugs (e.g. antidepressants) are given to &quot;classes&quot; of&#xD;
      patients (e.g. neuropathic pain patients). However, within those classes of patients very&#xD;
      different pain mechanisms are likely to underlie the pain condition in different patients. If&#xD;
      drugs affect part of these mechanisms, they will not work in all patients. Another reason for&#xD;
      variability in drug responses is genetic variation leading to a spectrum of different&#xD;
      responses to analgesics, from lack of efficacy to exaggerated responses, up to intolerable&#xD;
      adverse effects.&#xD;
&#xD;
      Quantitative sensory testing comprises methods that document alterations and reorganization&#xD;
      of the nociceptive system. Measuring an abnormal result in a chronic pain patient may provide&#xD;
      us with the information that the underlying pain pathways somehow must be altered. An&#xD;
      essential question is whether this information can be linked to drug efficacy in a&#xD;
      mechanism-based treatment approach. A further important question is whether assessing genetic&#xD;
      polymorphisms can explain different drug effects and hence help selecting the appropriate&#xD;
      therapeutic strategy for individual patients.&#xD;
&#xD;
      Objective&#xD;
&#xD;
      We will test the hypothesis that there is a correlation between disturbances in specific pain&#xD;
      mechanisms as assessed by quantitative sensory tests and analgesic efficacy after single-dose&#xD;
      drug administration in patients with chronic low back pain. Genetic factors affecting drug&#xD;
      metabolism and pain sensitivity will be analyzed as additional explanatory variables for drug&#xD;
      efficacy.&#xD;
&#xD;
      Methods&#xD;
&#xD;
      Quantitative sensory testing: Heat pain threshold and tolerance, Ice water testing with&#xD;
      central modulation of nociceptive input (DNIC), electrical pain detection and temporal&#xD;
      summation (skin probe), pressure algometry with pain detection and threshold Drugs&#xD;
      investigated: Imipramine, Oxycodone, Clobazam Blood samples: pharmacogenetics: Cytochrome&#xD;
      variants CYP2D6, CYP2C19, CYP3A4, COMT haplotypes, CGH-1 variants, A118G of mu opioid&#xD;
      receptor gene variants pharmacokinetics: kinetics of imipramine and desipramine&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in NRS(pain scale) between measurement after and before drug administration</measure>
    <time_frame>07/2012</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients global impression of change scale after drug administration</measure>
    <time_frame>07/2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacogenetic variables(see before)</measure>
    <time_frame>07/2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: measure of Imipramine and desipramine blood levels</measure>
    <time_frame>07/2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reliability of repeated quantitative sensory testing in the same patient</measure>
    <time_frame>12/2010</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Low Back Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxycodone 15mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clobazam 20mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Imipramine 75mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tolterodine 1mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone 15mg</intervention_name>
    <description>15mg single administration p.o.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clobazam</intervention_name>
    <description>20mg single administration p.o.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipramine</intervention_name>
    <description>75mg single administration p.o.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolterodine</intervention_name>
    <description>1 mg single administration p.o.</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Low back pain with NRS&gt;2&#xD;
&#xD;
          -  Chronic low back pain since more than 6 months&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  use of pain medication other than paracetamol and ibuprofen in the last 7 days&#xD;
&#xD;
          -  suspicion of radicular pain&#xD;
&#xD;
          -  suspicion of intervertebral disk herniation&#xD;
&#xD;
          -  foraminal intervertebral stenosis&#xD;
&#xD;
          -  suspicion of polyneuropathy&#xD;
&#xD;
          -  diabetes&#xD;
&#xD;
          -  parkinson disease&#xD;
&#xD;
          -  alzheimer disease&#xD;
&#xD;
          -  glaucoma&#xD;
&#xD;
          -  prostata hyperplasia or voiding problems&#xD;
&#xD;
          -  known heart rhythm problems&#xD;
&#xD;
          -  heart insufficiency NYHA 3-4&#xD;
&#xD;
          -  Systemic inflammatory disease&#xD;
&#xD;
          -  Ongoing oncologic disease&#xD;
&#xD;
          -  drug or alcohol abuse&#xD;
&#xD;
          -  Significant depressive disease (BDI-FS&gt;9)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Curatolo, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Bern, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Siegenthaler, Dr Med</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Bern, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pascal H Vuilleumier, Dr Med</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Bern, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Andreas Siegenthaler</name>
      <address>
        <city>Dep. of Anesthesiolgy and Pain therapy</city>
        <state>Bern University Hospital</state>
        <zip>3010 Bern</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD005454. Review.</citation>
    <PMID>17943857</PMID>
  </reference>
  <results_reference>
    <citation>Arendt-Nielsen L, Yarnitsky D. Experimental and clinical applications of quantitative sensory testing applied to skin, muscles and viscera. J Pain. 2009 Jun;10(6):556-72. doi: 10.1016/j.jpain.2009.02.002. Epub 2009 Apr 19. Review.</citation>
    <PMID>19380256</PMID>
  </results_reference>
  <results_reference>
    <citation>Foulkes T, Wood JN. Pain genes. PLoS Genet. 2008 Jul 25;4(7):e1000086. doi: 10.1371/journal.pgen.1000086. Review.</citation>
    <PMID>18654615</PMID>
  </results_reference>
  <results_reference>
    <citation>Curatolo M, Arendt-Nielsen L, Petersen-Felix S. Central hypersensitivity in chronic pain: mechanisms and clinical implications. Phys Med Rehabil Clin N Am. 2006 May;17(2):287-302. Review.</citation>
    <PMID>16616268</PMID>
  </results_reference>
  <results_reference>
    <citation>Markenson JA, Croft J, Zhang PG, Richards P. Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial. Clin J Pain. 2005 Nov-Dec;21(6):524-35.</citation>
    <PMID>16215338</PMID>
  </results_reference>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>August 10, 2010</study_first_submitted>
  <study_first_submitted_qc>August 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2010</study_first_posted>
  <last_update_submitted>April 5, 2016</last_update_submitted>
  <last_update_submitted_qc>April 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2016</last_update_posted>
  <responsible_party>
    <name_title>Dr Med Andreas Siegenthaler</name_title>
    <organization>Inselspital Bern</organization>
  </responsible_party>
  <keyword>Quantitative sensory testing</keyword>
  <keyword>Drug efficacy</keyword>
  <keyword>Low back pain syndrome</keyword>
  <keyword>Imipramine</keyword>
  <keyword>Oxycodone</keyword>
  <keyword>Clobazam</keyword>
  <keyword>Tolterodine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Clobazam</mesh_term>
    <mesh_term>Imipramine</mesh_term>
    <mesh_term>Tolterodine Tartrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

